SCHEMBL17855356

SCHEMBL17855356

c1ccc(C2(c3ccccc3)c3ccccc3-c3c(N(c4ccc(-c5ccc(-c6ccc7oc8ccccc8c7c6)cc5)cc4)c4ccc(-c5cccc(-c6ccc7oc8ccccc8c7c6)c5)cc4)cccc32)cc1

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 4/20 0.35
PLA2G4A P47712 4/20 0.35
PLA2G10 O15496 1/20 0.35
HSP90AA1 P07900 1/20 0.31
HSP90AB1 P08238 1/20 0.31
PRKDC P78527 1/20 0.30
KDM4E B2RXH2 1/20 0.30
MEN1 O00255 1/20 0.30
NPC1 O15118 1/20 0.30
ALDH1A1 P00352 1/20 0.30
MAPT P10636 1/20 0.30
HPGD P15428 1/20 0.30
RAB9A P51151 1/20 0.30
KMT2A Q03164 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
ALOX5 P09917 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17855387 1.00 PLA2G2A (0.35) PLA2G2APLA2G4APLA2G10HSP90AA1HSP90AB1
SCHEMBL23769978 1.00 PLA2G2A (0.35) PLA2G2APLA2G4APLA2G10HSP90AA1HSP90AB1
SCHEMBL17855186 1.00 PLA2G2A (0.35) PLA2G2APLA2G4APLA2G10HSP90AA1HSP90AB1
SCHEMBL23769980 0.99 PLA2G2A (0.35) PLA2G2APLA2G4APLA2G10HSP90AA1HSP90AB1
SCHEMBL23769777 0.99 PLA2G2A (0.35) PLA2G2APLA2G4APLA2G10HSP90AA1HSP90AB1
SCHEMBL22402032 0.99 PLA2G2A (0.35) PLA2G2APLA2G4APLA2G10HSP90AA1HSP90AB1
SCHEMBL17855100 0.98 PLA2G2A (0.34) PLA2G2APLA2G4APLA2G10HSP90AA1HSP90AB1
SCHEMBL17854976 0.98 PLA2G2A (0.33) PLA2G2APLA2G4APLA2G10HSP90AA1HSP90AB1
SCHEMBL17855184 0.98 PLA2G2A (0.33) PLA2G2APLA2G4APLA2G10HSP90AA1HSP90AB1
SCHEMBL17855352 0.98 PLA2G2A (0.33) PLA2G2APLA2G4APLA2G10HSP90AA1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160181525-A1 COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2016-06-23 US disclosed
US-20160181525-A1 COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2016-06-23 US disclosed
US-20150165055-A1 CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO CERULEAN PHARMA INC. (US) 2015-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150165055-A1 CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO SDCBP, DDOST, CD47 PLA2G2A 4036/4885PLA2G4A 3823/4885PLA2G10 4091/4885
US-20160181525-A1 COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE ESR1, ESR2, CCNE2 PLA2G2A 2495/4885PLA2G4A 3219/4885PLA2G10 2125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.